LIVNNasdaqElectromedical & Electrotherapeutic ApparatusFiscal year ends December 31
LivaNova PLC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$78.14+0.56 (+0.72%)
Close on Oct 19, 2026
- Market cap
- $4.40B
- P/E (TTM)
- 23.1
- Dividend yield
- –
LivaNova PLC revenue by segment
By business segment
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2015 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cardiopulmonary | $785.39M | $683.51M | $604.11M | $514.20M | $482.98M | $446.73M | $504.72M | – | – | – | 56.6% | +14.9% |
| Neuromodulation | $592.81M | $554.22M | $519.71M | $476.99M | $456.17M | $354.44M | $424.55M | $422.99M | $374.98M | – | 42.7% | +7.0% |
| Advanced Circulatory Support | – | – | $40.32M | $39.30M | $55.46M | $42.32M | $31.92M | – | – | – | – | – |
| Cardiovascular | – | – | – | – | – | – | – | $681.83M | $635.52M | $0 | – | – |
| Cardiac Rhythm Management | – | – | – | – | – | – | – | – | – | $0 | – | – |
| Neuromodulation | – | – | – | – | – | – | – | $422.99M | $374.98M | $291.56M | – | – |
| Cardiopulmonary | – | – | – | – | – | $577.08M | $656.65M | $681.83M | $635.52M | – | – | – |
| Operating income | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2015 | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Neuromodulation | $215.47M | $195.31M | $153.38M | $172.78M | $169.50M | – | – | – | – | – | +10.3% |
| Cardiopulmonary | $108.30M | $76.85M | $26.41M | $11.25M | -$6.43M | – | – | – | – | – | +40.9% |
| Advanced Circulatory Support | – | – | -$117.42M | -$142.59M | $2.20M | – | – | – | – | – | – |
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2015 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cardiopulmonary | – | – | – | – | – | $446.73M | $504.72M | $536.41M | $497.32M | – | – | – |
| Heart Valves | – | – | – | – | – | $88.03M | $120.01M | $125.96M | $138.19M | – | – | – |
| Advanced Circulatory Support | – | – | – | – | – | $42.32M | $31.92M | $19.46M | $0 | – | – | – |
By region
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2015 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $739.57M | $695.08M | $635.04M | $571.56M | $571.30M | $468.63M | $546.48M | $553.41M | $494.72M | $235.71M | 53.3% | +6.4% |
| Rest of World | $379.30M | $338.32M | $303.71M | $271.45M | $262.54M | $272.24M | $314.50M | $324.55M | – | – | 27.3% | +12.1% |
| Europe | $269.18M | $220.03M | $214.79M | $178.80M | $201.52M | $193.37M | $223.18M | $229.00M | $210.47M | $41.48M | 19.4% | +22.3% |
| United Kingdom | $55.90M | $48.90M | $41.50M | $32.30M | $35.80M | $29.70M | $37.70M | $34.80M | $30.80M | – | 4.0% | +14.3% |
| Rest of world [Member] | – | – | – | – | – | – | – | – | $307.08M | $14.36M | – | – |
| Rest of World | – | – | – | – | – | – | $314.50M | $324.55M | $307.09M | – | – | – |
From the segment and revenue-disaggregation notes of LivaNova's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.